Unknown

Dataset Information

0

AR-V7 exhibits non-canonical mechanisms of nuclear import and chromatin engagement in castrate-resistant prostate cancer.


ABSTRACT: Expression of the AR splice variant, androgen receptor variant 7 (AR-V7), in prostate cancer is correlated with poor patient survival and resistance to AR targeted therapies and taxanes. Currently, there is no specific inhibitor of AR-V7, while the molecular mechanisms regulating its biological function are not well elucidated. Here, we report that AR-V7 has unique biological features that functionally differentiate it from canonical AR-fl or from the second most prevalent variant, AR-v567. First, AR-V7 exhibits fast nuclear import kinetics via a pathway distinct from the nuclear localization signal dependent importin-α/β pathway used by AR-fl and AR-v567. We also show that the dimerization box domain, known to mediate AR dimerization and transactivation, is required for AR-V7 nuclear import but not for AR-fl. Once in the nucleus, AR-V7 is transcriptionally active, yet exhibits unusually high intranuclear mobility and transient chromatin interactions, unlike the stable chromatin association of liganded AR-fl. The high intranuclear mobility of AR-V7 together with its high transcriptional output, suggest a Hit-and-Run mode of transcription. Our findings reveal unique mechanisms regulating AR-V7 activity, offering the opportunity to develop selective therapeutic interventions.

SUBMITTER: Kim S 

PROVIDER: S-EPMC9398446 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

AR-V7 exhibits non-canonical mechanisms of nuclear import and chromatin engagement in castrate-resistant prostate cancer.

Kim Seaho S   Au CheukMan C CC   Jamalruddin Mohd Azrin Bin MAB   Abou-Ghali Naira Essam NE   Mukhtar Eiman E   Portella Luigi L   Berger Adeline A   Worroll Daniel D   Vatsa Prerna P   Rickman David S DS   Nanus David M DM   Giannakakou Paraskevi P  

eLife 20220718


Expression of the AR splice variant, androgen receptor variant 7 (AR-V7), in prostate cancer is correlated with poor patient survival and resistance to AR targeted therapies and taxanes. Currently, there is no specific inhibitor of AR-V7, while the molecular mechanisms regulating its biological function are not well elucidated. Here, we report that AR-V7 has unique biological features that functionally differentiate it from canonical AR-fl or from the second most prevalent variant, AR-v567. Firs  ...[more]

Similar Datasets

| S-EPMC5311967 | biostudies-literature
| S-EPMC6678978 | biostudies-literature
| S-EPMC7581977 | biostudies-literature
| S-EPMC6150493 | biostudies-literature
| S-EPMC8452729 | biostudies-literature
| S-EPMC10563598 | biostudies-literature
| S-EPMC11844536 | biostudies-literature
| S-EPMC10895308 | biostudies-literature
| S-EPMC7940541 | biostudies-literature
| S-EPMC8197232 | biostudies-literature